Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: procedure (653), etiquette (1), practice (614)

MyelomaBortezomib SC DexamethasonePabinostat 28 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (SC)-DEXAMETHASONE-PANOBINOSTAT (28 day) Regimen • Multiple Myeloma – Bortezomib (SC)-Dexamethasone-Panobinostat (28 day) Indication • Panobinostat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-SC-DexamethasonePabinostat-28-day.pdf

MyelomaBortezomib SC DexamethasonePabinostat 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (SC)-DEXAMETHASONE-PANOBINOSTAT (21 day) Regimen • Multiple Myeloma – Bortezomib (SC)-Dexamethasone-Panobinostat (21 day) Indication • Panobinostat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-SC-DexamethasonePabinostat-21day-Ver1.1.pdf

MyelomaBortezomib IV DexamethasonePabinostat 28 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT (28 day) Regimen • Multiple Myeloma – Bortezomib (IV)-Dexamethasone-Panobinostat (28 day) Indication • Panobinostat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostat-28-day.pdf

MyelomaBortezomib IV DexamethasonePabinostat 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT (21 day) Regimen • Multiple Myeloma – Bortezomib (IV)-Dexamethasone-Panobinostat (21 day) Indication • Panobinostat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostat-21day-Ver1.1.pdf

HSCTAlemtuzumabBusulphan-12-Fludarabine-VUD-Methotrexate-GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-BUSULFAN (12 doses)-FLUDARABINE-METHOTREXATE (GvHD) Volunteer Unrelated Donor (VUD) CONDITIONING This regimen will only
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabBusulphan-12-Fludarabine-VUD-Methotrexate-GvHD.pdf

Docetaxel-Pertuzumab/TrastuzumabSC

Description: Chemotherapy Protocol BREAST CANCER Docetaxel-Pertuzumab/Trastuzumab SC Regimen • Breast Cancer – Docetaxel-Pertuzumab/Trastuzumab SC Indication • Treatment of metastatic breast cancer
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Docetaxel-PertuzumabTrastuzumabSC.pdf

VenetoclaxLow

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (low risk) Funding may be required for this regimen. Regimen • CLL – Venetoclax (low risk) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxLow.pdf

IdelalisibRituximab

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Idelalisib-Rituximab Regimen • CLL – Idelalisib-Rituximab Indication • Chronic lymphocytic leukaemia in adults when the disease
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/IdelalisibRituximab.pdf

STHW841-V1-Biomerieux-Blood-culture-guidance

Description: BLOOD CULTURE A key investigation for diagnosis of bloodstream infections OUR SPECIAL THANKS GO TO Dr Susan M. Novak-Weekley Ph.D. D
Url: /Media/SUHTExtranet/DepartmentOfInfection/STHW841-V1-Biomerieux-Blood-culture-guidance.pdf

Using our facilities

Description: Auto Generated Title If you have an experimental, early phase or complex late-phase study you can benefit form access
Url: /ClinicalResearchinSouthampton/For-researchers/Using-our-facilities/Using-our-facilities.aspx

621 to 630 of 698

Previous … 61 62 63 64 65 … Next